Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making

Metastatic adenoid cystic carcinomas (ACCs) can cause significant morbidity and mortality. Because of their slow growth and relative rarity, there is limited evidence for systemic therapy regimens. Recently, molecular profiling studies have begun to reveal the genetic landscape of these poorly understood cancers, and new treatment possibilities are beginning to emerge. The objective is to use whole-genome and transcriptome sequencing and analysis to better understand the genetic alterations underlying the pathology of metastatic and rare ACCs and determine potentially actionable therapeutic targets. We report five cases of metastatic ACC, not originating in the salivary glands, in patients enrolled in the Personalized Oncogenomics (POG) Program at the BC Cancer Agency. Genomic workup included whole-genome and transcriptome sequencing, detailed analysis of tumor alterations, and integration with existing knowledge of drug–target combinations to identify potential therapeutic targets. Analysis reveals low mutational burden in these five ACC cases, and mutation signatures that are commonly observed in multiple cancer types. Notably, the only recurrent structural aberration identified was the well-described MYB-NFIB fusion that was present in four of five cases, and one case exhibited a closely related MYBL1-NFIB fusion. Recurrent mutations were also identified in BAP1 and BCOR, with additional mutations in individual samples affecting NOTCH1 and the epigenetic regulators ARID2, SMARCA2, and SMARCB1. Copy changes were rare, and they included amplification of MYC and homozygous loss of CDKN2A in individual samples. Genomic analysis revealed therapeutic targets in all five cases and served to inform a therapeutic choice in three of the cases to date.

[1]  E. Pleasance,et al.  Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Iwama,et al.  Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies , 2017, The Journal of experimental medicine.

[3]  P. Jänne,et al.  Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models , 2017, Clinical Cancer Research.

[4]  M. Ahn,et al.  Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14‐01) , 2017, Cancer.

[5]  C. Moskaluk,et al.  A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma , 2017, Clinical Cancer Research.

[6]  E. Lenkiewicz,et al.  A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma , 2017, Oncotarget.

[7]  M. Berger,et al.  The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform , 2017, JAMA oncology.

[8]  C. Antonescu,et al.  A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  I. Ellis,et al.  Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer , 2016, Modern Pathology.

[10]  M. Hyrcza,et al.  Gene of the month: BAP1 , 2016, Journal of Clinical Pathology.

[11]  R. Weber,et al.  In‐depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type , 2016, Cancer.

[12]  R. Ferrarotto,et al.  MYB-fusions and other potential actionable targets in adenoid cystic carcinoma , 2016, Current opinion in oncology.

[13]  L. Wood,et al.  Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma , 2016, Cancer Prevention Research.

[14]  T. Gonda,et al.  Adenoid Cystic Carcinoma Can Be Driven by MYB or MYBL1 Rearrangements: New Insights into MYB and Tumor Biology. , 2016, Cancer discovery.

[15]  D. Hayes,et al.  Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Huining Kang,et al.  Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. , 2016, Cancer discovery.

[17]  P. A. Futreal,et al.  Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations , 2015, Clinical Cancer Research.

[18]  M. Stratton,et al.  Clock-like mutational processes in human somatic cells , 2015, Nature Genetics.

[19]  Steven J. M. Jones,et al.  Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers , 2015, Cold Spring Harbor molecular case studies.

[20]  O. Mariani,et al.  Genomic landscape of adenoid cystic carcinoma of the breast , 2015, The Journal of pathology.

[21]  B. Carneiro,et al.  Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling , 2015, Oncotarget.

[22]  P. Bradley,et al.  Adenoid cystic carcinoma of the head and neck--An update. , 2015, Oral oncology.

[23]  Diane D. Liu,et al.  Phase II study of gefitinib in patients with advanced salivary gland cancers , 2015, Head & neck.

[24]  J. Xie,et al.  NOTCH1 signaling contributes to cell growth, anti-apoptosis and metastasis in salivary adenoid cystic carcinoma , 2014, Oncotarget.

[25]  Steven J. M. Jones,et al.  JAGuaR: Junction Alignments to Genome for RNA-Seq Reads , 2014, PloS one.

[26]  P. Stephens,et al.  Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies , 2014, The American journal of surgical pathology.

[27]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[28]  M. Stratton,et al.  Whole exome sequencing of adenoid cystic carcinoma. , 2013, The Journal of clinical investigation.

[29]  C. Moskaluk,et al.  Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming. , 2013, The Journal of clinical investigation.

[30]  Benjamin J. Raphael,et al.  The Mutational Landscape of Adenoid Cystic Carcinoma , 2013, Nature Genetics.

[31]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[32]  Thomas Krausz,et al.  BAP1 and cancer , 2013, Nature Reviews Cancer.

[33]  M. Stratton,et al.  Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.

[34]  R. Ferris,et al.  Molecular biology of adenoid cystic carcinoma , 2012, Head & neck.

[35]  L. Siu,et al.  A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[37]  J. Reis-Filho,et al.  Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers , 2012, The Journal of pathology.

[38]  P. A. Futreal,et al.  Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome , 2011, Clinical Cancer Research.

[39]  A. Argiris,et al.  A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck , 2011, Cancer.

[40]  R. Chole,et al.  Adenoid cystic carcinoma: a rare clinical entity and literature review. , 2011, Oral oncology.

[41]  Steven J. M. Jones,et al.  De novo assembly and analysis of RNA-seq data , 2010, Nature Methods.

[42]  R. Weber,et al.  Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance , 2010, Clinical Cancer Research.

[43]  J. Reis-Filho,et al.  Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas) , 2010, Journal of Clinical Pathology.

[44]  H. Horlings,et al.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.

[45]  Inanç Birol,et al.  De novo transcriptome assembly with ABySS , 2009, Bioinform..

[46]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[47]  L. Mariani,et al.  Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. , 2009, Oral oncology.

[48]  Steven J. M. Jones,et al.  Abyss: a Parallel Assembler for Short Read Sequence Data Material Supplemental Open Access , 2022 .

[49]  A. Chase,et al.  Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. , 2007, Blood.

[50]  D. Hayes,et al.  Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Y. Anavi,et al.  Adenoid Cystic Carcinoma of the Salivary Glands: A 20-year Review with Long-Term Follow-Up , 2005, Ear, nose, & throat journal.

[52]  E. Lamont,et al.  Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Roh,et al.  Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. , 2003, Archives of otolaryngology--head & neck surgery.

[54]  T. Saku,et al.  Basement membranes in adenoid cystic carcinoma an immunohistochemical study , 1992, Cancer.

[55]  M. Hallett,et al.  Absolute assignment of breast cancer intrinsic molecular subtype. , 2015, Journal of the National Cancer Institute.